Feasibility of a cannabidiol (CBD)-dominant cannabis-based medicinal product (CBMP) for the treatment of Long COVID symptoms: A single arm open-label feasibility trial.

Hannah ThurgurMichael LynskeyAnne Katrin SchlagCarol CroserDavid John NuttElizabeth Iveson

Published in: British journal of clinical pharmacology (2023)

The study drug was safe and well tolerated, demonstrating feasibility of CBD-dominant CBMPs in individuals diagnosed with Long COVID. However, there were limitations in research design related to recruitment strategy demonstrating a lack of feasibility in the approach implemented in this study. Future work with larger samples and incorporating a control group are required to test the efficacy of this treatment.

Keyphrases

coronavirus disease
sars cov
open label
clinical trial
study protocol
randomized controlled trial
emergency department
phase iii
phase ii
squamous cell carcinoma
combination therapy
physical activity
sleep quality
rectal cancer
adverse drug
drug induced